Onkocare uses liquid biopsy diagnostic technology, which only requires a tube of blood to be collected By detecting and analyzing the degree of DNA methylation, it can determine whether the patient has a tumor and determine the type and progression of the tumor

Based on the detection results of 6 lung cancer related DNA methylation sites and 1 sample quality reference site, combined with the self-developed DNA methylation hypersensitivity joint detection technology and the accumulation of over 10000 tumor samples, an Al big data algorithm model was formed for comprehensive evaluation to determine the risk level of lung cancer in the tested individuals

Based on the independently developed DNA methylation hypersensitivity joint detection technology and the Al big data algorithm model formed by the accumulation of over ten thousand tumor samples, Onkocare conducted a comprehensive evaluation to accurately capture the abnormal signals of liver early trace methylation and determine the risk level of liver cancer in the tested individuals

To make up for the shortcomings in the existing diagnostic plans for cervical cancer, Onkocare Life Technology conducted big data screening based on public databases of cervical cancer related methylation sites, combined with algorithm optimization, and ultimately selected four high-performance targeted gene sites Based on this, a DNA methylation detection product for cervical exfoliated cells was developed This product detects the DNA methylation status of four genes related to cervical lesio

Using Onkocare s unique DNA methylation hypersensitivity detection technology, the DNA methylation status of trace amounts of intestinal exfoliated cells in the blood is detected to evaluate whether the DNA originates from colon cancer or precancerous lesions, achieving non-invasive, accurate, and rapid cancer detection